Gabrielle Scott
Nurse Practitioner · Toledo, OHNPI 1457967614
Payments from drug & device makers
Across 460 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$843
- Biogen$831
- UCB, Inc.$550
- Pfizer$461
- Amgen$340
- plus $3K from 32 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$7,09397%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 144 | $1,567 |
| Novartis | 46 | $843 |
| Biogen | 44 | $831 |
| UCB, Inc. | 33 | $550 |
| Pfizer | 25 | $461 |
| Amgen(2 entities) | 21 | $340 |
| SK Life Science, Inc. | 15 | $263 |
| Teva Pharmaceuticals USA, Inc. | 15 | $243 |
| Neurelis, Inc. | 11 | $209 |
| Johnson & Johnson | 7 | $188 |
| EMD Serono, Inc. | 10 | $178 |
| Acadia Pharmaceuticals Inc | 9 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $128 |
| Eisai Inc. | 1 | $123 |
| AstraZeneca(2 entities) | 6 | $122 |
| Genentech USA, Inc. | 6 | $114 |
| Jazz Pharmaceuticals Inc. | 5 | $105 |
| Lundbeck LLC | 6 | $103 |
| Lilly USA, LLC | 6 | $83 |
| CSL Behring | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Aquestive Therapeutics, Inc. | 4 | $54 |
| Kyowa Kirin, Inc. | 4 | $54 |
| Catalyst Pharmaceuticals, Inc. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Acorda Therapeutics, Inc | 3 | $42 |
| Argenx US, Inc. | 2 | $38 |
| Merz Pharmaceuticals, LLC | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Biocodex, Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| TG Therapeutics, Inc. | 1 | $16 |
| Aprecia Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$150
- Leqembi$123
- NURTEC ODT$118
- KESIMPTA$100
How this compares
$7,332 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 44 | $397,400 |
| TecfideraDimethyl Fumarate | 31 | $276,479 |
| AubagioTeriflunomide | 27 | $250,238 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $124,714 |
| UbrelvyUbrogepant | 54 | $56,210 |
| FingolimodFingolimod Hcl | 13 | $29,747 |
| Dimethyl Fumarate | 30 | $29,582 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $23,163 |
| QuliptaAtogepant | 13 | $18,991 |
| Nurtec OdtRimegepant Sulfate | 14 | $13,905 |
| Dalfampridine ErDalfampridine | 27 | $10,268 |
| Pregabalin | 77 | $2,216 |
| Gabapentin | 124 | $1,848 |
| Pyridostigmine Bromide | 17 | $1,521 |
| Teriflunomide | 26 | $1,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $831 | $276,47931 claims |
| AbbVieUbrelvy, Qulipta | $1,567 | $75,20167 claims |
| PfizerNurtec Odt | $461 | $13,90514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Toledo
- Vaughn HobletToledo$19K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.